See more : Chart Industries, Inc. (GTLS-PB) Income Statement Analysis – Financial Results
Complete financial analysis of Spectrum Pharmaceuticals, Inc. (SPPI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Spectrum Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- PT Carsurin Tbk (CRSN.JK) Income Statement Analysis – Financial Results
- Electra Battery Materials Corporation (ELBM.V) Income Statement Analysis – Financial Results
- Gentrack Group Limited (GTK.AX) Income Statement Analysis – Financial Results
- DHT Holdings, Inc. (DHT) Income Statement Analysis – Financial Results
- One World Lithium Inc. (OWLI.CN) Income Statement Analysis – Financial Results
Spectrum Pharmaceuticals, Inc. (SPPI)
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Boston, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.11M | 0.00 | 0.00 | 22.62M | 109.33M | 128.37M | 146.44M | 162.56M | 186.83M | 155.85M | 267.71M | 192.96M | 74.11M | 38.03M | 28.73M | 7.67M | 5.67M | 577.00K | 258.00K | 1.00M | 2.37M | 41.11K | 1.00 | 1.00 | 100.00K | 100.00K | 100.00K |
| Cost of Revenue | 1.79M | 0.00 | 0.00 | 12.01M | 26.76M | 47.22M | 35.84M | 27.69M | 27.04M | 28.58M | 46.63M | 33.84M | 17.44M | 8.15M | 1.19M | 0.00 | 97.00K | 397.00K | 123.00K | 0.00 | 0.00 | 0.00 | -1.13M | -519.88K | -500.00K | -200.00K | 0.00 |
| Gross Profit | 8.32M | 0.00 | 0.00 | 10.61M | 82.58M | 81.15M | 110.60M | 134.87M | 159.79M | 127.27M | 221.07M | 159.13M | 56.67M | 29.88M | 27.53M | 7.67M | 5.58M | 180.00K | 135.00K | 1.00M | 2.37M | 41.11K | 1.13M | 519.88K | 600.00K | 300.00K | 100.00K |
| Gross Profit Ratio | 82.28% | 0.00% | 0.00% | 46.91% | 75.53% | 63.22% | 75.52% | 82.97% | 85.53% | 81.66% | 82.58% | 82.46% | 76.47% | 78.57% | 95.85% | 100.00% | 98.29% | 31.20% | 52.33% | 100.00% | 100.00% | 100.00% | 112,813,400.00% | 51,987,600.00% | 600.00% | 300.00% | 100.00% |
| Research & Development | 42.20M | 87.30M | 109.38M | 79.33M | 94.96M | 65.90M | 58.94M | 50.77M | 69.66M | 46.67M | 42.54M | 27.72M | 57.30M | 21.06M | 26.68M | 33.29M | 17.87M | 12.60M | 6.95M | 3.68M | 12.73M | 20.61M | 38.77M | 20.06M | 8.50M | 4.50M | 600.00K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 38.82M | 60.41M | 60.36M | 61.37M | 90.70M | 84.27M | 87.35M | 86.51M | 97.41M | 99.32M | 91.97M | 72.55M | 48.55M | 33.61M | 15.16M | 11.58M | 13.60M | 7.50M | 5.98M | 7.62M | 4.10M | 7.58M | 5.11M | 3.47M | 3.10M | 2.30M | 700.00K |
| Other Expenses | -5.33M | -10.89M | -2.94M | -8.89M | 9.58M | 389.00K | 887.00K | -1.25M | -4.37M | -722.00K | -844.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 81.02M | 147.70M | 169.73M | 140.70M | 213.75M | 177.81M | 172.23M | 175.60M | 191.36M | 166.06M | 141.25M | 103.99M | 109.57M | 58.39M | 42.00M | 44.87M | 31.47M | 20.10M | 12.94M | 11.31M | 16.83M | 28.19M | 45.00M | 24.04M | 12.10M | 7.00M | 1.30M |
| Cost & Expenses | 82.81M | 147.70M | 169.73M | 140.70M | 240.51M | 225.03M | 208.07M | 203.29M | 218.40M | 194.64M | 187.88M | 137.83M | 127.01M | 66.53M | 43.20M | 44.87M | 31.57M | 20.50M | 13.06M | 11.31M | 16.83M | 28.19M | 43.87M | 23.52M | 11.60M | 6.80M | 1.30M |
| Interest Income | 968.00K | 163.00K | 1.34M | 5.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.61M | 0.00 | 0.00 | 83.00K | 0.00 | 0.00 | 776.35K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 998.00K | 0.00 | 0.00 | -5.00M | 340.00K | 6.80M | 9.44M | 9.07M | 8.58M | 2.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 17.00K | 0.00 | 0.00 | 1.86M | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | -4.36M | 286.00K | 261.00K | 3.34M | 28.10M | 27.65M | 25.95M | 38.32M | 24.29M | 20.07M | 6.74M | 5.65M | 4.51M | 3.72M | 610.00K | 255.00K | 198.00K | 682.00K | 425.00K | 346.00K | 1.33M | 2.27M | 1.13M | 519.88K | 500.00K | 200.00K | -300.00K |
| EBITDA | -77.06M | -147.70M | -169.73M | -140.70M | -93.50M | -68.62M | -34.80M | -3.66M | -11.65M | -21.58M | 86.57M | 63.69M | -52.40M | -25.45M | -10.33M | -40.08M | -26.28M | -20.52M | -12.38M | -9.81M | -9.92M | -25.68M | -42.74M | -20.78M | -11.20M | -7.20M | -1.50M |
| EBITDA Ratio | -761.91% | 0.00% | 0.00% | -622.14% | -85.52% | -53.46% | -23.76% | -2.25% | -6.23% | -13.85% | 32.34% | 33.01% | -70.70% | -66.93% | -35.94% | -522.41% | -463.18% | -3,556.15% | -4,797.29% | -980.80% | -418.13% | -62,458.85% | -4,273,686,000.00% | -2,077,988,900.00% | -11,200.00% | -7,200.00% | -1,500.00% |
| Operating Income | -72.70M | -147.70M | -169.73M | -144.03M | -131.18M | -96.66M | -61.63M | -40.73M | -31.57M | -38.79M | 79.82M | 55.13M | -52.90M | -28.51M | -19.17M | -37.20M | -25.89M | -19.92M | -12.80M | -10.47M | -17.51M | -28.15M | -43.87M | -23.52M | -11.50M | -6.70M | -1.20M |
| Operating Income Ratio | -718.78% | 0.00% | 0.00% | -636.89% | -119.98% | -75.30% | -42.08% | -25.06% | -16.90% | -24.89% | 29.82% | 28.57% | -71.37% | -74.97% | -66.74% | -484.81% | -456.43% | -3,452.69% | -4,961.24% | -1,046.80% | -738.28% | -68,469.52% | -4,387,369,500.00% | -2,352,312,900.00% | -11,500.00% | -6,700.00% | -1,200.00% |
| Total Other Income/Expenses | -5.36M | -10.73M | -1.60M | 174.20M | 11.17M | -11.37M | -9.20M | -9.65M | -11.96M | 2.15M | -844.00K | -2.91M | 4.01M | 8.74M | 3.70M | 3.14M | 581.00K | 1.28M | 2.00K | 78.00K | -126.50M | -200.69K | -8.70K | -2.22M | 200.00K | 700.00K | 300.00K |
| Income Before Tax | -78.06M | -158.43M | -171.33M | -144.59M | -120.01M | -108.03M | -70.83M | -50.38M | -43.53M | -36.64M | 78.98M | 52.22M | -48.89M | -19.77M | -22.71M | -34.06M | -25.31M | -18.64M | -12.80M | -10.62M | -20.72M | -28.35M | -43.88M | -25.75M | -11.30M | -6.00M | -900.00K |
| Income Before Tax Ratio | -771.78% | 0.00% | 0.00% | -639.37% | -109.77% | -84.15% | -48.36% | -30.99% | -23.30% | -23.51% | 29.50% | 27.06% | -65.96% | -51.99% | -79.04% | -443.90% | -446.18% | -3,231.02% | -4,960.47% | -1,061.90% | -873.80% | -68,957.67% | -4,388,239,700.00% | -2,574,649,400.00% | -11,300.00% | -6,000.00% | -900.00% |
| Income Tax Expense | 46.00K | 4.00K | -60.00K | -9.21M | 1.00K | -16.78M | -2.31M | 406.00K | 2.19M | 25.50M | -15.57M | 3.70M | -43.00K | -421.00K | 997.00K | -3.16M | -2.61M | -1.28M | -514.00K | 85.00K | 3.18M | -315.05K | 2.55M | 2.47M | 100.00K | -500.00K | 100.00K |
| Net Income | -78.10M | -158.44M | -171.27M | -135.39M | -120.01M | -91.25M | -68.51M | -50.79M | -45.72M | -62.13M | 94.55M | 48.52M | -48.84M | -19.05M | -15.47M | -34.04M | -23.28M | -18.64M | -12.29M | -10.39M | -17.63M | -27.83M | -46.43M | -25.99M | -11.60M | -6.20M | -1.00M |
| Net Income Ratio | -772.24% | 0.00% | 0.00% | -598.66% | -109.77% | -71.08% | -46.78% | -31.24% | -24.47% | -39.87% | 35.32% | 25.14% | -65.90% | -50.09% | -53.85% | -443.64% | -410.44% | -3,230.85% | -4,762.02% | -1,039.00% | -743.61% | -67,703.21% | -4,642,728,700.00% | -2,598,990,500.00% | -11,600.00% | -6,200.00% | -1,000.00% |
| EPS | -0.43 | -1.02 | -1.38 | -1.22 | -1.16 | -1.07 | -0.94 | -0.78 | -0.71 | -1.02 | 1.61 | 0.94 | -0.99 | -0.48 | -0.49 | -1.17 | -0.96 | -1.06 | -0.97 | -2.49 | -12.34 | -40.42 | -122.82 | -91.45 | -51.64 | -716.85 | -7.41 |
| EPS Diluted | -0.43 | -1.02 | -1.38 | -1.22 | -1.16 | -1.07 | -0.94 | -0.78 | -0.71 | -1.02 | 1.46 | 0.86 | -0.99 | -0.48 | -0.49 | -1.17 | -0.96 | -1.06 | -0.97 | -2.49 | -12.34 | -40.42 | -122.82 | -91.45 | -51.64 | -716.85 | -7.41 |
| Weighted Avg Shares Out | 183.24M | 154.86M | 124.39M | 110.59M | 103.31M | 85.12M | 72.82M | 64.88M | 64.71M | 60.73M | 58.59M | 53.27M | 49.50M | 39.27M | 31.55M | 29.01M | 24.31M | 17.66M | 12.67M | 4.17M | 1.43M | 688.62K | 378.02K | 284.20K | 224.62K | 8.65K | 134.98K |
| Weighted Avg Shares Out (Dil) | 183.24M | 154.86M | 124.39M | 110.59M | 103.31M | 85.12M | 72.82M | 64.88M | 64.71M | 60.73M | 64.64M | 57.96M | 49.50M | 39.27M | 31.55M | 29.01M | 24.31M | 17.66M | 12.67M | 4.17M | 1.43M | 688.62K | 378.02K | 284.20K | 224.62K | 8.65K | 134.98K |
7 Top Penny Stocks To Watch With Big News This Week
Penny Stocks With News Light Up The Scanners This Week This week
FRIDAY DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - January 31, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Spectrum Pharmaceuticals, Inc. ("Spectrum" or "the Company") (NASDAQ: SPPI) for violations of §§10(b)...
Spectrum Pharmaceuticals Provides Update on ROLVEDON™ (eflapegrastim-xnst) Injection and Announces Unaudited Fourth Quarter 2022 Financial Results
BOSTON--( BUSINESS WIRE )--Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology, today announced business highlights and preliminary ROLVEDON net sales for the quarter and year ended December 31, 2022.
SPPI ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of February 3, 2023 in the Class Action Filed on Behalf of Spectrum Pharmaceuticals, Inc. Shareholders
NEW YORK , Jan. 31, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) alleging that the Company violated federal securities laws. This...
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Spectrum Investors of a Lead Plaintiff Deadline of February 3, 2023
NEW YORK , Jan. 30, 2023 /PRNewswire/ -- Attention Spectrum Pharmaceuticals, Inc. ("Spectrum") (NASDAQ: SPPI) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors. This lawsuit is on behalf of...
SPPI DEADLINE: ROSEN, A RANKED AND LEADING FIRM, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SPPI
New York, New York--(Newsfile Corp. - January 29, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between December 6, 2021 and September 22, 2022, both...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spectrum Pharmaceuticals, Inc. of Class Acton Lawsuit and Upcoming Deadline - SPPI
NEW YORK , Jan. 27, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), and certain officers. The class action, filed in the United States District Court for the...
SPPI LAWSUIT ALERT: Levi & Korsinsky Notifies Spectrum Pharmaceuticals, Inc. Investors Of a Class Action Lawsuit and Upcoming Deadline
New York, New York--(Newsfile Corp. - January 27, 2023) - Levi & Korsinsky, LLP notifies investors in Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI) of a class action securities lawsuit.The lawsuit on behalf of Spectrum investors has been...
The 3 Best Biotech Stocks Under $1 to Buy for January
While biotech may be the next big thing, making money through it isn't easy. Indeed, investing in biotech stocks is often more of an art than a science.
SPECTRUM SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Spectrum To Contact Him Directly To Discuss Their Options
NEW YORK , Jan. 26, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI) and reminds investors of the February 3, 2023...
Source: https://incomestatements.info
Category: Stock Reports